Global Positive Allosteric Modulator Market

Positive Allosteric Modulator Market Overview

The global Positive Allosteric Modulator market was valued at USD 1,651.5 million in 2021 and is projected to hit around USD 2,911.3 million by 2028, expected to grow at a compound annual growth rate (CAGR) of 8.3% from 2022 to 2028. Allosteric modulators bind to a receptor and change their response to a stimulus. Positive allosteric modulators aid Agonist-mediated responses. Positive allosteric modulators are employed as a unique therapy strategy for patients with mental diseases such as dementia, schizophrenia, and others, estimated to drive the global market. Patients can be given positive allosteric modulators in combination with their existing approved anti-AD medicines to boost the efficacy of the drugs. In addition, the market is expected to expand primarily due to the rising number of cases of Alzheimer’s disease. Furthermore, according to the World Health Organization (WHO), 55 million people worldwide will have dementia by 2020, with approximately 10 million new cases per year. Alzheimer’s disease accounts for 60-70% of these cases. Moreover, allosteric modulators are used in medical research and drug development. According to World Bank data, healthcare expenditures accounted for 9.78% in 2018, while research and development expenditures accounted for 2.1%.

What is Positive Allosteric Modulator?

Positive allosteric modulators increase agonist affinity or efficacy. A substance’s affinity is its ability to bind to a receptor, while effectiveness is its ability to activate a receptor. The chemical is classified as an antagonist if its effectiveness is zero. GABAA receptor positive allosteric modulators are PAM compounds that increase the activity of the GABAA receptor protein in the central nervous system of vertebrates. GABAA receptor PAMs provide sedative and anxiolytic effects when used as medicines.

Growth Drivers

Rising Anxiety Disorders cases

According to the World Health Organization, the estimated number of persons living with anxiety disorders worldwide was 264 million in 2015, up 14.9% from the previous year. The growing elderly population reduced side effects, increased efficacy of new/innovative medications, and the rising frequency of anxiety and depression disorders are all driving this industry forward. Anxiety was a major sector of the worldwide allosteric modulator market in 2017 and is likely to remain so during the forecast period. The increase in demand for anxiety treatments and growth in the number of businesses investing in new anxiety drugs drove the market revenue.

Increasing Need for better and Effective Treatment Outcomes

Concerns about non-adherence to oral schizophrenia medication and the consequent return of symptoms are predicted to be other significant factors driving the global schizophrenia treatment market expansion. As a result, a type of schizophrenia treatment known as long-acting injectables has gained popularity (Los). The long-acting injectable (LAls) version is used in several important and recent medication approvals for schizophrenia. Based on these trends, several major market players are concentrating their efforts on developing this type of schizophrenia medication. Long-acting injectables have several advantages, including preventing patient non-adherence to medications and extending the medication’s presence in the body. Furthermore, the most important component of the long-acting injectable is that by preventing non-adherence, these schizophrenia medicines can successfully minimize the number of relapses, leading to cognitive and irreversible brain damage. The market is expected to increase rapidly during the projected period due to these long-acting injectables and their high efficacies.

Pre Covid-19 Impact on Global Positive Allosteric Modulator Market

Before pandemic, Companies are enhancing their product offerings and launching new products in response to advancements in diagnostic technologies and ongoing research activities in the field, which, when combined with other business expansion initiatives such as mergers and acquisitions, strategic collaboration, and new investments into other companies, are expected to complement the market’s growth over the forecast period.

Covid-19 Impact on Global Positive Allosteric Modulator Market

The COVID-19 pandemic has been transforming the growth of numerous markets, and the outbreak’s immediate impact is varied. While demand in a few industries has decreased, countless other areas may continue to thrive and offer potential growth prospects. Initially, the global COVID-19 outbreak and the lockdown scenario in several countries created some obstacles for the market, owing to hospitals and clinics’ refusal to provide services.

Post Covid-19 Impact on Global Positive Allosteric Modulator Market

Because the COVID-19 pandemic has disrupted the pharmaceutical supply chain, many items sold in various nations, such as the United States, Europe, and other countries, were affected by pharmaceutical manufacturing and export restrictions. Some pharmaceuticals are created in-house by pharmaceutical businesses, while others are manufactured in other countries, such as contract manufacturing services, which has impacted the product supply chain. As a result, the market expansion has been hampered by the delayed supply of second-generation antipsychotics in pharmacies and other end-user settings due to restrictions or cancellations on pharmaceutical export.

By Disease type

Based on the disease type, the market is categorized as Parkinson’s disease, Schizophrenia, Alzheimer’s disease, Others. The Parkinson’s disease segment is expected to hold a significant share of the global Positive Allosteric Modulator market over the forecast period. Parkinson’s disease is a neurodegenerative disease that primarily affects the areas of the brain responsible for movement control, making daily activities challenging. Parkinson’s disease is characterized by tremors, stiffness, trouble walking, and other symptoms caused by a decline in dopamine production. Many pharmaceutical companies are pursuing research to discover novel Parkinson’s disease therapies, creating strategic research cooperation. This will benefit market revenue as a result of this element. For instance, in October 2018, Pfizer Inc., a well-known pharmaceutical company, partnered with Bain Capital to launch Cerevel Therapeutics, a biopharmaceutical company focused on developing drugs for Parkinson’s disease and other central nervous systems disorders, boosting the Parkinson’s ricpAcp drugs market further.

By Drug type

The market is classified Galantamine, Benzodiazepines, Barbiturates, Amantadine, Donepezil, Levodopa, Others. The Benzodiazepines segment is estimated to have a significant share of the global Positive Allosteric Modulator market over the forecasted period by 2028. Anxiety, sleeplessness, panic disorder, seizures, and alcohol withdrawal are all treated with benzodiazepines, a class of psychotropic medicines. By boosting the impact of the neurotransmitter GABA, benzodiazepine medications generate a calming effect (Gamma-Aminobutyric Acid). Benzodiazepines are extensively prescribed medications around the world, and they can aid with anxiety disorders, seizures, sleep induction, and sedation before surgery or general anesthesia. An increase in the senior population, a hectic lifestyle, and everyday routines contribute to mental disturbances like anxiety, mania, and panic disorder. Due to an increase in the prevalence of anxiety, seizures, sleeplessness, and a surge in concern for avoiding stress and related diseases, the market for benzodiazepine medications is fast growing.

By Region Segment Analysis

Based on region segment, the market is bifurcated into North America, Europe, Asia-Pacific, South America, and The Middle East & Africa. North America is predicted to have the greatest market share over the projection period. Because of increasing health awareness among the population and easy access to quality healthcare in developed countries such as the United States, the market in North America is expected to obtain the biggest market share throughout the forecast period. Furthermore, the region’s increased investment in R&D activities is likely to enhance the market growth.

Competitors Analysis

The Companies Acadia Pharmaceuticals Inc., Eli Lilly and Company, Novartis AG, Sanofi-aventis Groupe, Bayer AG, Abbott Laboratories, Johnson & Johnson Services, Inc., Siemens Healthcare GmbH, Merck & Co., Inc., Pfizer Inc., and Other Prominent Players in the Positive Allosteric Modulator Market. Key Stakeholders

• Market research and consulting firms
• Industry Associations
• Local Governments
• Regulatory bodies
• Positive Allosteric Modulator Market providers
• Suppliers
• Retailers
• Service Providers

Recent Developments

• In February 2022, Acadia Pharmaceuticals Inc. announced the FDA submission of a supplemental New Drug Application (sNDA) for Pimavanserin to treat hallucinations and delusions associated with Alzheimer’s disease psychosis.
• In June 2020: Interim HealthCare Inc. launched a free dementia caregiver’s guide for home care for patients living with dementia or Alzheimer’s disease.

Scope of the Report

Report Attribute	Details
Market Size Value in 2021	USD 1,651.5 million
The revenue forecast in 2028	USD2,911.3 million
Growth Rate	CAGR of 8.3% from 2022 to 2028.
Historical data	2017 – 2020
Forecast period	2022 – 2028
Region covered	North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Key companies Profiled	The Companies Acadia Pharmaceuticals Inc., Eli Lilly and Company, Novartis AG, Sanofi-aventis Groupe, Bayer AG, Abbott Laboratories, Johnson & Johnson Services, Inc., Siemens Healthcare GmbH, Merck & Co., Inc., Pfizer Inc., and Other Prominent Players in the Positive Allosteric Modulator Market.

Market Modelling

By Disease Type

• Parkinson’s disease
• Schizophrenia
• Alzheimer’s disease
• Others

By Drug Type

• Galantamine
• Benzodiazepines
  • Diazepam
  • Clonazepam
  • Lorazepam
  • Lorazepam
• Barbiturates
  • Methohexital
  • Phenobarbital
  • Secobarbital
• Amantadine
• Donepezil
• Levodopa
• Others

By End-User

• Hospital
• Pharmacy
• Others

By Region

• North America
• Europe
• Asia-Pacific
• South America
• The Middle East & Africa

Antimicrobial Hospitals Curtains Market

Healthcare Supply Chain Management

Microalgae Market

E-Liquid Market

Video Analytics Market

Renewable Energy Market

Steam Mops Market

Starter Culture Market

CNC Knife Cutter Machine Market

Renewable Energy Market